Introduction {#s1}
============

Cutaneous leishmaniasis (CL) is endemic in more than 90 countries and 1 million new cases are estimated to be globally reported each year. Control of CL in the Americas is contingent upon active case detection and treatment. Although pentavalent antimonials (Sb^V^) remain the first-line treatment option, therapeutic failure rates of 19% to 75% challenge its usefulness ([@B31]; [@B45]). Adverse drug reactions (ADRs) have been reported to occur in up to 64% of individuals treated with these drugs ([@B27]), and can result in acute pancreatitis, hepatotoxicity, and death in most severe cases ([@B27]). The high rates of treatment failure and of ADR urge the identification of readily accessible and objectively measured biomarkers of therapeutic response and toxicity.

Populations most affected by CL in the Americas are inhabitants of rural dispersed communities with limited access to health care systems. The extended time for patient follow-up required to determine the therapeutic response (3 to 6 months) ([@B29]) constrains clinical follow-up and pharmacovigilance strategies. Identification of prognostic biomarkers for early definition of the therapeutic response could contribute to mitigate these limitations.

Pharmacometabolomic approaches have contributed to understanding the mechanism of action of drugs through identification of metabolic signatures associated with therapeutic responses ([@B19]). Although scantly applied in neglected tropical diseases research, metabolomics has been recently used to explore the mechanisms of antimonial drug resistance in *in vitro* cultures of *Leishmania donovani* and *Leishmania infantum*; polyamides and trypanothione biosynthetic pathways were identified as contributors to the resistance phenotype ([@B5]; [@B38]), concurring with previous findings at the genome and proteome levels ([@B30]).

The feasibility of obtaining human samples for metabolomics such as serum, plasma, saliva, or urine, and the lower complexity of data matrices resulting from the smaller dimension of the metabolome compared with the genome (from ∼30,000 genes to ∼2,500 metabolites) strongly support its application in the pipeline of biomarker discovery ([@B18]). The use of metabolomics toward therapeutics for neglected infectious diseases, such as leishmaniasis, has been underexploited. Only recently, [@B47] have documented the implementation of a liquid chromatography mass spectrometry (LC-MS) metabolic approach to identified biomarkers for diagnosis and definition of disease stage in human African trypanosomiasis. In this study we implemented an unbiased exploratory metabolomics approach to identify predictive and prognostic candidate biomarkers of the outcome of treatment with meglumine antimoniate (MA) in samples from patients with CL caused by *L. Viannia*, as well as to describe the metabolomic perturbations associated to drug exposure.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2_1}
----------------

This study was approved and monitored by the Institutional Review Board for Ethical Conduct of Research Involving Human Subjects of CIDEIM (approval code CIEIH 1209), in accordance with national and international guidelines for conduct of clinical studies. All individuals voluntarily participated in the study; each participant signed the informed written consent at recruitment.

Study Design and Participants {#s2_2}
-----------------------------

This metabolomics study was designed as a biomarker discovery study, aimed to determine the metabolic perturbations associated with exposure to antimonial drugs in CL patients, and to identify candidate biomarkers of antimonial treatment outcome in plasma samples ([**Figure 1**](#f1){ref-type="fig"}). Parasitologically diagnosed CL patients (n = 39), 18 to 47 years of age, with time of lesion evolution \<6 months and who had a reported overall adherence to treatment with MA \> 85% were included between years 2012 to 2015 ([**Table 1**](#T1){ref-type="table"}). Peripheral blood samples were taken before initiation of treatment and at the end of treatment from all participants. Healthy and non-treated controls were not included as the purpose of this study was to identify biomarkers of therapeutic responsiveness in infected patients and not biomarkers of infection. Sample size could not be calculated as no prior data was available for probabilistic estimations. Therefore, sample size for our discovery study was defined based on the well-established biomarker pipeline and respective sample dimensions: discovery studies (unbiased semiquantitative studies of small sample size---within the tens of samples), qualification studies (target-driven quantitative small sample size studies---tens of samples), verification studies (targeted quantitative studies with larger cohorts, usually within the hundreds of samples), and validation studies (cohort studies within the thousands of samples) ([@B35]).

![Flowchart of the study design.](fphar-10-00657-g001){#f1}

###### 

Clinical and demographic characteristics of study participants.

  Characteristic                                                Total           Responders      Nonresponders   p value\*
  ------------------------------------------------------------- --------------- --------------- --------------- -----------
  Number of participants                                        39 (100)        25 (64)         14 (36)         --
  Sex, n (%)                                                                                                    
   Male                                                         36 (92)         25 (100)        11 (78.6)       0.039^‡^
   Female                                                       3 (8)           --              3 (21.4)        
  Age in years, median (range)                                  30 (18--47)     30 (18--45)     29.5 (19--47)   0.735^§^
  Ethnicity, n (%)                                                                                              
   African descent                                              37 (95)         25 (100)        12 (85.7)       0.122^‡^
   Other                                                        2 (5)           --              2 (1.3)         
  Weight, mean (SD), kg                                         69.4 (8.4)      67.6 (7.4)      72.4 (9.6)      0.092^§^
  Time of disease evolution (months), median (range)            1 (1--5)        2 (1--5)        1 (1--5)        0.311^§^
  Number of lesions per patient, median (range)                 2 (1--6)        1 (1--5)        2 (1--6)        0.634^§^
  Percentage of treatment adherence, median (range)^†^          100 (85--100)   100 (98--100)   100 (85--100)   0.075^‡^
  Geographical area of reported infection (Department). n (%)                                                   
   Nariño                                                       32 (82.1)       20 (80)         12 (85.7)       0.655^‡^
   Other                                                        7 (17.9)        5 (20)          2 (14.3)        
  Isolated *Leishmania* species, n(%)                                                                           
   *L. V. panamensis*                                           31 (79.5)       19 (76)         12 (85.7)       0.813^‡^
   *L. V. braziliensis*                                         2 (5.1)         2 (8)           0               
   Not available or contaminated                                6 (15.4)        4 (16)          2 (14.3)        
  **Adverse Drug Reactions (ADR)**                                                                              
  Patients reporting adverse drug reactions, n (%)                                                              
   None                                                         12 (30.8)       6 (24)          6 (42.9)        0.286^‡^
   At least one                                                 27 (69.2)       19 (76)         8 (57.1)        
  Intensity of ADR, n (%)                                                                                       
   Mild                                                         24 (89)         17 (89)         7 (87)          1.000^‡^
   Moderate                                                     3 (11)          2 (11)          1 (13)          
  Type of reaction, n (%)                                                                                       
   Fever                                                        18 (26.1)       12 (29.3)       6 (21.4)        0.480^‡^
   Pain at the injection site                                   9 (13.0)        3 (7.3)         6 (21.4)        
   Headache                                                     9 (13.0)        7 (17.1)        2 (7.1)         
   Arthralgia                                                   9 (13.0)        5 (12.1)        4 (14.3)        
   Fatigue                                                      5 (7.2)         3 (7.2)         2 (7.1)         
   Myalgia                                                      5 (7.2)         4 (9.8)         1 (3.6)         
   Others                                                       14 (20.3)       7 (17.1)        7 (25.0)        

\*Contrast between responders and non-responders. ^†^Based on ampules received vs. ampules ordered. ^‡^Chi2/Fisher. ^§^T-test/Wilcoxon rank sum test.

Patients received standard-of-care treatment with MA (20 mg/kg/day for 20 days) and clinical evaluations were conducted at the end of treatment and 13 weeks after initiation of treatment, time at which clinical outcome was determined. Peripheral blood samples for isolation of plasma were obtained before initiation of treatment and within 8 days after end of treatment. The clinical outcome was defined according to the most recent harmonization guidelines for CL ([@B29], [@B28]). Cure was defined as complete reepithelialization and absence of inflammatory signs for all lesions. Treatment failure was defined as incomplete reepithelialization and/or presence of induration, raised borders, or other evidence of inflammation of any CL lesion at the end of follow-up (90 days after initiation of treatment); or reactivation of the original lesion(s); or appearance of new lesions during follow-up. Safety monitoring was performed and recorded during the follow-up visits. Adverse events (AE), were recorded and standardized (by name and severity) according to the Common Toxicity Criteria of the National Cancer Institute, V 4.0 ([@B25]). Causality was established using WHO-UMC criteria and the Naranjo algorithm ([@B24]) and were reported as possibly, probably, or definitely related to treatment with MA ([**Table 1**](#T1){ref-type="table"}), and thus considered ADRs. Quality control of clinical data included double data entry from paper case report forms (CRF) to a Microsoft Office Access database, external data monitoring, and resolution of discrepancies by consensus.

Sample Processing and Metabolite Extraction {#s2_3}
-------------------------------------------

Plasma was obtained from heparin anticoagulated peripheral blood samples by centrifugation at 800 × *g* for 10 min. For metabolite extraction we adapted the protocol described by [@B46], and all samples were processed in a single batch by the same person in the same day. Briefly, 100 μl of plasma was mixed with chloroform/methanol (in a 1:3 ratio), vortexed on a cooled (4°C) mixer for 1 h, centrifuged for 10 min at 14,000 × *g* at 4°C, and the supernatant transferred and stored at −80°C.

LC/MS Data Acquisition and Processing {#s2_4}
-------------------------------------

Samples were analyzed by hydrophilic interaction LC/MS (UltiMate 3000 RSLC, Thermo Fisher) using a 150 × 4.6 mm ZIC-pHILIC column (Merck SeQuant) running at 300 µl/min and Orbitrap Exactive (Thermo Fisher) detection. Mass spectrometer parameters were 50,000 resolving power in positive/negative switching mode. Electrospray ionization (ESI) voltage was 4.5 kV in positive and 3 kV in negative modes. Buffers consisted of (A) 20 mM ammonium carbonate (Sigma) in H~2~O and (B) Merck SeQuant: acetonitrile (Rathburn Chemicals). The gradient ran from 20% A: 80% B to 80% A: 20% B in 15 min, followed by a wash at 95% A: 5% B for 3 min, and equilibration at 20% A: 80% B for 5 min.

Raw mass spectrometry data were processed using XCMS ([@B40]), MzMatch ([@B39]), and in-house R-scripts for deep filtering, post-processing, and identification. Peaks were visualized using PeakML Viewer ([@B39]). The data were compiled using the IDEOM software ([@B8]). Classification of metabolite annotations followed the MSI guidelines ([@B41]). Compounds annotated on the basis of a \<3 ppm accurate mass threshold, searched against the IDEOM database, were described as "annotations," while compounds matched to an authentic standard with \<3 ppm accurate mass error and \<5% retention time deviation were classed as "identifications."

Quality Control of LC/MS Data {#s2_5}
-----------------------------

Aliquots from each sample were pooled to generate a quality control (QC) master sample. All samples were analyzed in 1 day and in one batch in a randomized manner. Stock solutions of 116 authentic standard compounds were prepared in ethanol, 50% ethanol/water, or Milli-Q water, depending on solubility ([**Figure S1**](#SM1){ref-type="supplementary-material"}). A working solution containing all authentic standards was prepared and run at the beginning and at the end of the run ([@B7]). The QC was injected before starting the LC/MS run and every five samples for stable run assurance. The quality of the chromatography and signal reproducibility was checked by analysis of QC samples, internal authentic standards, and total ion chromatograms. Samples that displayed unacceptable analytical variation (retention time drift) were removed from further analysis. Metabolites with more than 20% missing values, confidence identification \<5, and drug derivatives were excluded from the analysis. Additional manual curation was performed on all datasets confirming identification and removing false identifications based on peak quality.

Data Curation and Statistical Analysis {#s2_6}
--------------------------------------

Clinical and demographic data were analyzed using R software version 3.3.2 and STATA 14, using untransformed data. For metabolomic data, principal component analysis (PCA) analysis was used to identify outlier samples. MetaboAnalyst 4.0 ([@B6]), XCMS, and GraphPad Prism 6 were used for data analysis and interpretation. Peak intensity table was normalized by probabilistic quotient normalization ([@B10]), generalized log transformed, and Pareto scaled ([@B43]). A statistical pipeline based on univariate (Student's t-test and ANOVA) and multivariate analyses \[orthogonal partial least squares discriminant analyses (OPLS-DA)\] was used to identify metabolites associated with drug exposure, toxicity, and treatment outcome. OPLS-DA statistics R^2^Y and Q^2^ represent the total sum of variation in Y explained by the model, and the goodness of prediction calculated by full cross-validation, respectively ([@B49]). KEGG, MetaboAnalyst 4.0, and text mining were used for pathway analyses ([@B6]). ROC curves were constructed by logistic regression.

Cytotoxicity Assay {#s2_7}
------------------

Cytotoxicity of candidate metabolites was evaluated in THP-1 cells in dose response experiments: allantoin (0.005 mM--31 mM) and turine (0.05 mM--10 mM). The range of allantoin doses was selected based on its maximum solubility in RPMI medium (≈31 mM) and FDA-approved doses for local therapy as a skin protectant (≈31--126 mM) ([@B12]). Taurine concentrations were based on those found in plasma in healthy individuals ([@B23]) and those reported as cytoprotective concentrations ([@B11]). One hundred thousand cells were seeded in a 96-well plate in RPMI medium supplemented with 10% FBS and incubated at 37°C, 5% CO~2~ with allantoin or taurine for 72 h. Cytotoxicity was evaluated using the MTT (3-(4,5-dimethylthiazol-2-yl)-​2,5-diphenyltetrazolium bromide) method following the manufacturer's instructions (ATCC) ([**Figure S2**](#SM1){ref-type="supplementary-material"}).

PBMCs Isolation, *Ex Vivo* Infection, and Parasite Survival Assays {#s2_8}
------------------------------------------------------------------

Blood samples were collected from six CL patients before initiation of treatment. Peripheral blood mononuclear cells (PBMCs) were isolated by centrifugation over a Histopaque 1077 gradient (Sigma-Aldrich). PBMCs were resuspended in RPMI with 10% FBS and seeded in 96-well plates. Cells were infected in a 1:10 parasite-to-monocyte ratio for 24 h with serum-opsonized *L.V. panamensis* (transfected with the luciferase reporter gene) as previously optimized and described ([@B15]). Taurine or allantoin (Sigma-Aldrich) were added alone or in combination (simultaneous exposure) with 4 μg/ml MA for 72 h at 34°C, 5% CO~2~, and parasite burden was evaluated by luminometry ([@B15]).

Results {#s3}
=======

Clinical and Demographic Characteristics of Study Participants {#s3_1}
--------------------------------------------------------------

A total of 39 participants were included in this study, 25 who responded to MA treatment and 14 who did not respond ([**Table 1**](#T1){ref-type="table"}, [**Figure 1**](#f1){ref-type="fig"}). The majority of participants (92%) were young adult males of Afro-Colombian descent from the department of Nariño, Colombia. No significant differences were found in demographic or clinical characteristics between groups, with the exception of gender where the only three female participants were recruited to the treatment failure group (p = 0.04). At least one ADR was found in 27 participants (69%), the most common ones being fever (18.4%) followed by pain at the injection site (9.2%) and headache (9.2%) ([**Table 1**](#T1){ref-type="table"}). No serious adverse events were reported.

Exposure to MA Alters the Plasma Metabolome of CL Patients {#s3_2}
----------------------------------------------------------

Based on the raw metabolite data, metabolomes from four patients (three responders and one of the female non-responders) were excluded from further analyses; two of them had poor quality peak spectra, while the other two were identified as outliers in the PCA ([**Figure S3**](#SM1){ref-type="supplementary-material"}). No statistical differences in clinical and demographic variables were found among groups after outlier exclusion. After data curation and quality control, from a total of 11,309 features, 536 metabolites were detected in plasma samples and 48 metabolites were identified against authentic pure standards ([**Dataset S1**](#SM2){ref-type="supplementary-material"}). The remaining 488 metabolites were classified as annotated. *N*-methyl glucamine (meglumine), a by-product of MA, was detected in all post-treatment samples (relative mean intensity 26.734) serving as an indicator of drug exposure in the study population; this metabolite was excluded from further analysis.

The abundance of 30.4% of detected metabolites (163 of 536) was significantly modified after *in vivo* exposure to MA \[paired t-test p ≤ 0.05, false discovery rate (FDR) ≤0.1\], 19 of which were identified against an authentic pure standard. Fifty-three percent (88 of 163) were more abundant after treatment ([**Figure 2A**](#f2){ref-type="fig"} and [**Dataset S2**](#SM3){ref-type="supplementary-material"}). To select metabolites that were consistently modified after antimonial drug exposure, data were analyzed by OPLS-DA. Of the 163 differentially abundant metabolites found by paired t-test analysis, 38 were also discriminatory by OPLS-DA (sum R^2^Y = 0.93 and cross-validation test Q^2^ = 0.62; cutoff thresholds of 1.5 ≤ p\[1\] ≤ -1.5 and 0.3 ≤ p (corr)\[1\] ≤ -0.3 in the S-plot; [**Dataset S2**](#SM3){ref-type="supplementary-material"} and [**Figure S4**](#SM1){ref-type="supplementary-material"}). Among these, six metabolites were identified: betaine, choline phosphate, D-ribose, L-carnitine, S-malate, and xanthine ([**Figure 2B**](#f2){ref-type="fig"}). The relative abundance of betaine, xanthine, and D-ribose increased after treatment, while S-malate, choline phosphate, and L-carnitine decreased. Both annotated and identified metabolites were included for metabolic pathway analysis, showing that metabolites within the pathways of long-chain fatty acid metabolism and β-oxidation (L-carnitine and choline phosphate, 3-methylglutarylcarnitine, and cis-5-tetradecenoylcarnitine), redox balance (choline phosphate, guanidinoacetate, S-malate, L-dehydroascorbate, and betaine), and nucleotide metabolism (S-dihydroorotate, 3-methylguanine, D-ribose and xanthine) were significantly and differentially abundant after MA exposure ([**Dataset S2**](#SM3){ref-type="supplementary-material"}).

![Exposure to meglumine antimoniate alters the plasma metabolome of CL patients. Plasma samples from CL patients (n = 35) obtained before (Pre) and at the end of treatment (Post) with MA were analyzed by LC/MS. **(A)** Heatmap representation of the normalized relative intensity of metabolites with significantly different abundance between samples obtained before and at the end of treatment, built using Euclidean distance and ward clustering algorithm. **(B)** Paired dot plot of identified metabolites significantly modulated after treatment with MA. Data were normalized using the pooled sample from the pre-treatment group. Statistical significance in dot plots was determined using paired t-test. \*p \<0.0.](fphar-10-00657-g002){#f2}

Metabolites Associated With Wound Healing and Redox Balance Are Differentially Abundant in Responders and Non-Responders {#s3_3}
------------------------------------------------------------------------------------------------------------------------

An OPLS-DA model was constructed to select metabolites that could discriminate between patients that cured (responders, n = 22) and patients that did not cure (non-responders, n = 13). Pre-treatment and end-of-treatment plasma samples were included for this analysis. The model allowed separation of samples from responders and non-responders with a sum R^2^Y: 0.96 and cross-validation test Q^2^: 0.55 ([**Figure 3A**](#f3){ref-type="fig"}). Cutoff thresholds of 0.65 ≤ p\[1\] ≤ -0.65 and 0.3 ≤ p (corr)\[1\] ≤ -0.3 in the S-plot were defined for selection of the most discriminatory metabolites. Of 30 metabolites with discriminatory potential, 26 were annotated and 4 were identified against an authentic pure standard ([**Dataset S3**](#SM4){ref-type="supplementary-material"}).

![Metabolites associated with wound healing and redox balance are more abundant in CL patients who cured. **(A)** OPLS-DA model of metabolites depicts the separation of all samples (pre- and post-treatment) in each group (responders and non-responders), each circle representing an individual sample. **(B)** Scatter dot plots of selected metabolites differentially abundant between responders and non-responders. Whiskers represent the 5--95 percentile. Data were normalized using the pooled sample from plasmas of the responders group. Statistical significance was determined using t-test. \*p \<0.05.](fphar-10-00657-g003){#f3}

A four-way ANOVA with Fisher´s LSD *post hoc* analysis was conducted to strengthen selection of candidate metabolites predictive and prognostic of the therapeutic response ([**Dataset S3**](#SM4){ref-type="supplementary-material"}). In this analysis, 30 metabolites could discriminate responders from non-responders, 4 of these exclusively in pre-treatment samples (p ≤ 0.05, FDR ≤ 0.1), 11 exclusively in post-treatment samples, and 15 in both pre- and post-treatment plasma samples ([**Dataset S3**](#SM4){ref-type="supplementary-material"}). Seventeen differentially abundant metabolites were also found as discriminatory by OPLS-DA. Of these, 13 were annotated and 4 identified ([**Table 2**](#T2){ref-type="table"}).

###### 

Plasma metabolites with significant differences in CL patients that responded or did not respond to MA treatment.

  Metabolites^‡^                     Elemental formula     Mass (Da)   RT (min)   *p* value   FDR       *Post hoc* Fisher's LSD\*
  ---------------------------------- --------------------- ----------- ---------- ----------- --------- ---------------------------
  **Taurine^§^**                     C~2~H~7~NO~3~S        125.01      13.55      0.00028     0.00948   1-2; 3-4
  **Allantoin^§^**                   C~4~H~6~N~4~O~3~      158.04      13.28      0.00324     0.05261   1-2; 3-4
  ***N*-acetylglutamine^§^**         C~7~H~12~N~2~O~4~     188.08      10.57      0.00805     0.09197   1-2; 3-4
  **Pyruvate^§^**                    C~3~H~4~O~3~          88.016      7.93       0.01005     0.09606   1-2; 3-4
  D-erythrose                        C~4~H~8~O~4~          120.04      10.34      0.00012     0.00600   1-2; 3-4
  Taurochenodeoxycholate-3-sulfate   C~26~H~45~NO~9~S~2~   289.63      4.34       0.00017     0.00723   1-2; 3-4
  Ala-Lys-Ser-Arg                    C~18~H~36~N~8~O~6~    230.14      13.27      0.00019     0.00743   1-2; 3-4
  Glycochenodeoxycholate 7-sulfate   C~26~H~43~NO~8~S      264.64      4.66       0.00038     0.01079   3-4
  2-Hydroxypyridine                  C~5~H~5~NO            95.04       7.98       0.00076     0.01951   1-2; 3-4
  FA methyl jasmonate                C~13~H~20~O~3~        224.14      3.94       0.00162     0.03192   1-2; 3-4
  N6-methyl-L-lysine                 C~7~H~16~N~2~O~2~     160.12      19.26      0.00427     0.06468   1-2; 3-4
  ethylpyruvate                      C~5~H~8~O3            116.05      5.34       0.00435     0.06468   1-2; 3-4
  Fatty acyls^¶^                     C~13~H~18~O~5~        254.12      5.25       0.00459     0.06650   1-2; 3-4
  Glu-Phe-Trp                        C~25~H~28~N~4~O~6~    240.1       7.71       0.00558     0.07844   1-2; 3-4
  Sterol lipids^\|\|^                C~24~H~40~O4          392.29      4.83       0.00855     0.09197   1-2
  N5-ethyl-L-glutamine               C~7~H~14~N~2~O~3~     174.1       12.66      0.00900     0.09197   1-2; 3-4
  Stearoylcarnitine                  C~25~H~49~NO~4~       427.37      4.72       0.00945     0.09197   3-4

^‡^Data was normalized using a pooled sample from responders, gLog~2~ transformed and pareto scaled. RT: retention time in minutes, mass in Daltons.

^\*^Group contrasts with statistical significance in the Fisher LSD post hoc: 1: responders pre-treatment, 2: non-responders pre-treatment, 3: responders post-treatment, 4: non-responders post-treatment.

^§^ **In bold**, metabolites identified against an authentic pure standard.

^¶^\[FA methyl_hydroxyl_oxo(5:2/4:0)\] methyl 4-\[2-(2-formyl-vinyl)-3-hydroxy-5-oxo-cyclopentyl\]-butanoate.

^\|\|^\[ST hydrox\] 3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid.

Of the annotated metabolites, six were related to lipid metabolism (two fatty acyls, taurochenodeoxy-cholate-3-sulfate, glycochenodeoxycholate 7-sulfate, sterol lipids, and stearoylcarnitine), two with energy metabolism (D-erythrose and ethylpyruvate), and five with amino acid metabolism (N5-ethyl-L-glutamine, N6-methyl-L-lysine, 2 hydroxypyridine, Glu-Phe-Trp, and Ala-Lys-Ser-Arg) ([**Table 2**](#T2){ref-type="table"}). All identified metabolites (taurine, *N*-acetylglutamine, allantoin, and pyruvate) participate in antioxidant and wound healing responses, and were consistently found more abundant in responders both in pre- and post-treatment samples ([**Figure 3B**](#f3){ref-type="fig"}). Among identified metabolites, the abundance of taurine and allantoin significantly increased at the end of treatment in patients who responded to treatment, in contrast to non-responders ([**Figure 3B**](#f3){ref-type="fig"}). Allantoin, *N*-acetylglutamine, taurine, and pyruvate had both predictive and prognostic potential as determined by ROC curves of data from pre-treatment and post-treatment samples, respectively (AUC \>0.7) ([**Figure 4**](#f4){ref-type="fig"}). ROC curve analyses of the individual metabolites or a composite metabolic signature including allantoin, *N*-acetylglutamine, taurine, and pyruvate showed that taurine had the highest predictive and prognostic potential in our patient cohort (AUC = 0.75 and AUC = 0.82, respectively) ([**Figure 4**](#f4){ref-type="fig"}).

![Metabolites with predictive and prognostic potential of treatment outcome. ROC curves represent the area under the curve (AUC) of the false-positive rate vs. the true positive rate. Data from all samples for each individual metabolite, or the combination of the four selected metabolites (ALL), were used to construct the ROC curves. ROC curves of metabolites identified in pre-treatment samples are shown in the left and in post-treatment samples in the right. CI: confidence interval.](fphar-10-00657-g004){#f4}

Allantoin Promotes MA-Dependent Killing of *L.V. Panamensis* {#s3_4}
------------------------------------------------------------

Allantoin and taurine have been described as important mediators of wound healing and participate in antioxidant responses ([@B2]; [@B11]; [@B20]). Based on this, we explored whether these metabolites could enhance the antimony-mediated killing of *Leishmania*. PBMCs from CL patients were infected *ex vivo* with *L. V. panamensis* and exposed to 10 mM taurine or 10 mM allantoin alone or in combination with MA. Selection of these doses was based on concentrations not cytotoxic for cells, and in the case of allantoin we also consider the minimum dose allowed by FDA for use as a topical treatment and its solubility in RPMI medium. Exposure to taurine or allantion alone, or taurine in combination with MA, did not modify the parasite burden of infected PBMCs. However, when infected cells were exposed to allantoin in combination with MA (4 µg/mL), parasite killing was significantly enhanced compared to the MA-only control ([**Figure 5**](#f5){ref-type="fig"}), indicating a potential contribution of allantoin in antimony-mediated parasite killing.

![Allantoin potentiates antimony-mediated killing of intracellular *Leishmania*. Peripheral blood mononuclear cells from six CL patients were infected *ex vivo* with *L. V. panamensis* (L.p.) for 24 h. Taurine (10 mM) or allantoin (10 mM) was added alone or in combination with MA (4 μg/ml) for 72 h, and parasite burden was evaluated by luminometry. Shown is the percent parasite survival relative to infected and untreated cells. Statistical significance was determined by t-test. \*p \< 0.05.](fphar-10-00657-g005){#f5}

Discussion {#s4}
==========

Despite the high rates of treatment failure and ADRs, systemic pentavalent antimonials remain the first-line treatment for CL. Unnecessary exposure of patients to these highly toxic drugs should be minimized, and thus identification of predictive biomarkers of treatment outcome is a priority in the clinical management of CL. Assessment of therapeutic response for CL is conducted at 3 and 6 months after initiation of treatment. However, the occurrence of CL in dispersed rural settings constrains access to treatment, treatment follow-up, and pharmacovigilance actions. Thus, early predictors of the therapeutic response (predictive and prognostic biomarkers) could support public health interventions and clinical practice. In this study, we provide the first metabolomic profiles of CL patients undergoing treatment with pentavalent antimonials, and report a set of predictive and prognostic candidate biomarkers of therapeutic outcome to be scaled toward biomarker validation studies. Increased levels of allantoin, taurine, and *N*-acetylglutamine, metabolites involved in antioxidant and wound healing responses, were detected before and at the end of treatment in patients who cured. This supports the fact that induction of host immune/wound healing responses during treatment, in addition to controlling the parasite burden, is central to therapeutic cure, and furthermore highlights a previously unrecognized participation of antioxidant mechanisms in healing of CL.

Exposure to metalloids such as antimony results in disturbance of ATP production, induction of oxidative and osmotic stress (in part due to production of reactive oxygen species), lipid peroxidation, and downstream loss of membrane integrity ([@B14]; [@B33]; [@B50]; [@B3]). Drug-induced perturbation of metabolites associated with redox balance is reflected by the significant increase in betaine, D-ribose, and xanthine and decrease of choline phosphate and S-malate at the end of treatment. Betaine protects against osmotic stress ([@B26]) and redox imbalances primarily through homocysteine conversion to methionine ([@B13]). Reduced abundance of choline phosphate is consistent with its oxidation to betaine and with the higher levels of betaine found after treatment with MA. D-ribose and xanthine are metabolites within purine biosynthetic pathways. Their higher abundance after drug treatment could contribute to protection against metal-induced oxidative stress through the oxidative branch of the pentose phosphate pathway by production of NADPH and purine degradation to urate, the major antioxidant in the blood ([@B32]). These results provide evidence that the plasma metabolome of CL patients exposed to MA reflects a response against the oxidative stress induced by antimonial drugs.

The mechanisms of action of antimonials are not fully understood ([@B9]; [@B14]; [@B27]). It has been shown that exposure to antimonials leads to inhibition of fatty acid β-oxidation, and this has been considered part of the mechanism(s) of antileishmanial action ([@B4]; [@B9]). However, how these drugs modulate fatty acid β-oxidation is still unknown. Our results showed that L-carnitine, a facilitator of fatty acid transport to the mitochondria for β-oxidation ([@B44]), was less abundant at the end of treatment in CL patients, compared to pre-treatment samples. Concordantly, other acylcarnitine intermediates (3-methylglutarylcarnitine and cis-5-tetradecenoylcarnitine) associated with dysfunction of normal fatty acid β-oxidation ([@B37]; [@B48]; [@B44]; [@B36]) were increased after MA treatment. These results suggest that reduced lipid transport to the mitochondria could contribute to the MA-induced perturbations in fatty acid β-oxidation or metabolic adaptations to the stressor. Although these inferences derive from observations of human plasma samples and reflect the functions of host cells, these same mechanisms could also be operating in *Leishmania* cells; however, this remains to be demonstrated.

In our study, plasma metabolites involved in inflammatory and oxidative stress pathways were identified as candidate biomarkers of the outcome of treatment. ROC curve analyses showed that taurine, allantoin, pyruvate, and *N*-acetylglutamine had the potential to be both predictive and prognostic biomarkers in our patient cohort. *N*-acetylglutamine, allantoin, and taurine have important roles in the control of oxidative stress, regulation of inflammatory responses ([@B22]; [@B17]; [@B23]; [@B1]), and in wound healing ([@B20]; [@B11]; [@B2]). Both the immune response and exposure to MA generate a strong oxidative environment within the human host. In this context, the first host response to this oxidizing environment is to increase antioxidant defense mechanisms. We speculate that increased antioxidant capacity in patients who respond to treatment, portrayed by higher levels of allantoin, taurin, and *N*-acetylglutamine, reflects higher oxidative stress, which in turn, could contribute to enhanced drug and ROS-mediated parasite killing, favoring therapeutic cure.

Allantoin, a downstream product of purine degradation, has been used as skin protectant in dermatological conditions ([@B16]; [@B20]; [@B21]). The oxidative stress induced upon exposure to MA could result in production of allantoin from purine degradation and urate interconversion. Higher abundance of taurine and allantoin in CL patients who cured, together with the evidence that allantoin promotes antimony-mediated parasite killing, concurs with their biological role as skin protectants and enhancers of wound healing, suggesting that in addition to serving as putative biomarkers of outcome, these metabolites could also contribute to drug-induced healing of CL through host-targeted mechanisms.

Leishmaniasis has been historically more frequently reported in adult males, primarily due to occupational exposure ([@B42]). This contributes to one of the limitations of this study, which was the minimal inclusion of women for metabolomic profiling and the absence of children samples in the analyses. Considering the discovery nature of our study design, the target population was controlled as much as possible in terms of age, sex, ethnicity, and geographical region of origin to reduce demographic variability that could influence the metabolic profiles and that could skew candidate biomarkers selection. This limitation should be addressed in future validation studies using targeted metabolomics in larger patient cohorts that are age and sex matched, where the current data will serve as the basis for probabilistic estimation of the sample size.

Metabolic profiling of samples obtained by techniques of minimal invasiveness, such as collection of serum/plasma, urine, or saliva, facilitates the identification of biomarkers with a high potential to be translatable to the clinic. Implementation of metabolomics in neglected infectious disease research is just emerging, and most exploratory studies have been conducted in the context of African and American trypanosomiasis ([@B34]; [@B47]). Our discovery study reports the first plasma metabolomes of CL patients undergoing treatment with first-line MA, and provides the knowledge base for follow-up studies by establishing a set of candidate biomarkers to move forward to the validation, verification, and qualification phases of the pipeline of biomarkers of therapeutic responsiveness in CL.

Results presented here highlight the participation of metabolites mediating antioxidant and wound healing responses in clinical cure of CL, paving the way for the unexplored field of immunometabolomics, as a tool to inform novel therapeutics for leishmaniasis. Combination therapies of antileishmanial drugs and immunomodulators constitute one of the main approaches for novel antileishmanial therapies, seeking to reduce parasite burden while restoring immune homeostasis. A combination therapy of antimony and topical allantoin will constitute a next study phase, aiming to optimize antileishmanial treatment by reducing the exposure to toxic antimony doses, while promoting a healing response. Together, these results provide the research community with a set of well-defined candidate biomarkers for future validation, and constitute an important step toward urgently needed, clinically implementable methods to provide personalized medicine approaches for CL treatment.
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